Search results
Jul 3, 2021 · The vaccine mRNA BNT-162b2 is publicly available [ 3 ]. The sequence of mRNA-1273 was taken from Jeong et al. [ 4 ], and should be considered putative. However, the 5′-UTR of this putative sequence is identical to one of the 5′-UTR sequences (SEQ ID NO 181) in a Moderna patent [ 18 ].
- Table 1
(1) Coding sequences of ribosomal proteins (34 and 53 in the...
- NC_045512
1. Severe acute respiratory syndrome coronavirus 2 isolate...
- PMC Free Article
Wolin SL, Walter P. Ribosome pausing and stacking during...
- Table 1
A Known DNA (or RNA) Sequence Can Serve as the Basis for an mRNA Vaccine, Which is then Formulated with Lipid Nanoparticles (LNPs) Buffers. mRNA-1273 encodes for the full-length Spike Protein in the Pre-fusion Conformation (S-2P) mRNA-1273 Preclinical & Clinical Programs.
Aug 5, 2020 · Here we show that mRNA-1273 induces potent neutralizing antibody responses to both wild-type (D614) and D614G mutant 2 SARS-CoV-2 as well as CD8 + T cell responses, and protects against...
- Kizzmekia S. Corbett, Darin K. Edwards, Sarah R. Leist, Olubukola M. Abiona, Seyhan Boyoglu-Barnum, ...
- 2020
Jul 14, 2020 · The candidate vaccine mRNA-1273 encodes the stabilized prefusion SARS-CoV-2 spike protein. Methods. We conducted a phase 1, dose-escalation, open-label trial including 45 healthy adults, 18 to...
- Lisa A. Jackson, Evan J. Anderson, Nadine G. Rouphael, Paul C. Roberts, Mamodikoe Makhene, Rhea N. C...
- 2020
Dec 30, 2020 · The mRNA-1273 vaccine showed 94.1% efficacy at preventing Covid-19 illness, including severe disease. Aside from transient local and systemic reactions, no safety concerns were identified.
- Lindsey R. Baden, Hana M El Sahly, Brandon J Essink, Karen Kotloff, Sharon Frey, Rick Novak, David D...
- 2021
Aug 25, 2021 · The Moderna vaccine candidate mRNA-1273 was also highly effective, and showed 86.4% efficacy in volunteers ≥65 years old, in comparison with 95.6% efficacy in 18–65-year-old volunteers 131.
Sep 22, 2021 · Published September 22, 2021. N Engl J Med 2021;385: 1774 - 1785. DOI: 10.1056/NEJMoa2113017. VOL. 385 NO. 19. Abstract. Background. At interim analysis in a phase 3, observer-blinded,...
